|
|
Post by sportsrancho on Dec 14, 2017 10:08:10 GMT -5
I got permission to share with you guys my friends opinion of the meeting....
It was an interesting meeting. Kresa opened it and had a lot to say. When he was asked politely why he was still there after a long career he said Al Mann was a close friend and the he was going to see that his dream comes true. He also stated that he wants to see the rest of the drugs in the pipeline succeed. I think his buy was desperately needed to keep things going so he stepped up. They new they had the vote before the meeting started. Mike is amazing. He answered everybody’s questions and when Kresa wanted to adjourn the meeting Mike said he would stay. When asked about Symphony vs IMS he said Symphony was what they have been using because IMS is more expensive, but more detailed and their estimates have alway been on Symphony. He added as cash gets better they may add IMS too. They are closely monitoring the affects of TV campaign and are getting good results in those regions. I asked about Brazil and UAE and he didn’t have a definitive time frame on Brazil which I found odd. The EAU he said was turned down because he would have had to manage too many partners and he had that problem at Amgen. Several shareholders were there with the idea of voting no but he explained to them that since they only had 4 million shares that wasn’t enough to do anything like acquisitions (which he mentioned more than once). He said that they have cash to run two quarters and compared that to Tesla who also only has two quarters of operating cash. He assured everyone that the share would be used to expand the company and would only be used sparingly if need to keep the lights on while cash flow from Afrezza breaks even. When asked about his projection for break even he said that would be included in his 2018 guidance. From his demeanor I read it should be very positive.
|
|
|
|
Post by Clement on Dec 14, 2017 11:17:05 GMT -5
Acquisitions?
"they only had 4 million shares that wasn’t enough to do anything like acquisitions (which he mentioned more than once)"
What do you think Mike C has in mind?
Now?
|
|
|
|
Post by kite on Dec 14, 2017 11:34:36 GMT -5
Acquisitions? "they only had 4 million shares that wasn’t enough to do anything like acquisitions (which he mentioned more than once)" What do you think Mike C has in mind? Now? We can make many speculations but it's probably best to just wait and see until news break |
|
|
|
Post by madog365 on Dec 14, 2017 11:46:24 GMT -5
Really silly for MNKD to even be considering doing any acquisitions...Any money they have should be going into selling Afrezza , funding pediatric and trep t trials. Those shares should be used to generate funding and get partnerships. I still don't understand whether they really believe they can go at this alone in the long run.
|
|
|
|
Post by xanet on Dec 14, 2017 12:03:25 GMT -5
Acquisitions? "they only had 4 million shares that wasn’t enough to do anything like acquisitions (which he mentioned more than once)" What do you think Mike C has in mind? Now? Didn't someone say Mike wanted to acquire AMGN? Or was that AAPL? Yeah, I think it was AAPL; much better fit. |
|
|
|
Post by compound26 on Dec 14, 2017 12:14:37 GMT -5
Really silly for MNKD to even be considering doing any acquisitions...Any money they have should be going into selling Afrezza , funding pediatric and trep t trials. Those shares should be used to generate funding and get partnerships. I still don't understand whether they really believe they can go at this alone in the long run. I think it all depends on what the acquisition is and whether the acquisition is value-creating to the Mannkind shareholders. Let's suppose Mannkind acquires One Drop for certain number of Mannkind shares. If One Drop is actually cash flow positive right now and is expected to grow its cash flow further in the future and if Mannkind paid a good price (from the perspective of the Mannkind shareholders), I would not object to such an acquisition. |
|
|
|
Post by casualinvestor on Dec 14, 2017 12:18:21 GMT -5
He did mention TSLA....
I agree that they are hardly in a position to be throwing money around. But there are probably some smaller private companies that have something that would be good for a new pipeline drug. Really, Like Someone that they've already worked with. I see this as a longer term benefit. TREP-T is something I would like to get an update on, as it should be the next product?
|
|
|
|
Post by madog365 on Dec 14, 2017 12:56:25 GMT -5
Really silly for MNKD to even be considering doing any acquisitions...Any money they have should be going into selling Afrezza , funding pediatric and trep t trials. Those shares should be used to generate funding and get partnerships. I still don't understand whether they really believe they can go at this alone in the long run. I think it all depends on what the acquisition is and whether the acquisition is value-creating to the Mannkind shareholders. Let's suppose Mannkind acquires One Drop for certain number of Mannkind shares. If One Drop is actually cash flow positive right now and is expected to grow its cash flow further in the future and if Mannkind paid a good price (from the perspective of the Mannkind shareholders), I would not object to such an acquisition. It's highly unlikely that a tech company like one drop would be cash flow positive at this stage in the game. And if they somehow were, they wouldn't be selling to Mannkind on the cheap. There's a part of me that fears that Mannkind will "acquire" Receptor. Perhaps they purposely established this company to secretly develop a project they did not want to have to disclose as a public company. I don't know but that would not look good without a really good explanation. |
|
|
|
Post by timri on Dec 14, 2017 13:25:58 GMT -5
I think it all depends on what the acquisition is and whether the acquisition is value-creating to the Mannkind shareholders. Let's suppose Mannkind acquires One Drop for certain number of Mannkind shares. If One Drop is actually cash flow positive right now and is expected to grow its cash flow further in the future and if Mannkind paid a good price (from the perspective of the Mannkind shareholders), I would not object to such an acquisition. It's highly unlikely that a tech company like one drop would be cash flow positive at this stage in the game. And if they somehow were, they wouldn't be selling to Mannkind on the cheap. There's a part of me that fears that Mannkind will "acquire" Receptor. Perhaps they purposely established this company to secretly develop a project they did not want to have to disclose as a public company. I don't know but that would not look good without a really good explanation. I agree that would be a really tough sell right now. Although the cannabis market is exploding. Working in healthcare heroin and pain pill addiction is out of control. If they had a non addictive pain management system that worked I think that would out weigh buying a company in the type of position we currently are. I’m finally seeing a tipping point where doctors don’t want to prescribe heavy meds anymore bc they have seen the mess they created in the last 20 years. Adding cannabis along with afrezza and trep could be huge value |
|
|
|
Post by centralcoastinvestor on Dec 14, 2017 13:39:43 GMT -5
Thinking of acquisitions, perhaps they could be focused on a small acquisition of a company that can spread the footprint of Afrezza more rapidly. I'm not sure what form of company that would fit though. Just a thought.
|
|
|
|
Post by boca1girl on Dec 14, 2017 13:47:54 GMT -5
I also thought of RLS as the “acquisition” target. I just don’t see how now would be the right time.
|
|
|
|
Post by slugworth008 on Dec 14, 2017 13:48:27 GMT -5
Really silly for MNKD to even be considering doing any acquisitions...Any money they have should be going into selling Afrezza , funding pediatric and trep t trials. Those shares should be used to generate funding and get partnerships. I still don't understand whether they really believe they can go at this alone in the long run. I agree. The only thing they should be acquiring is higher sales numbers - IMO |
|
|
|
Post by afrezzamiracle on Dec 14, 2017 13:49:40 GMT -5
Our sales force could use another drug or two to peddle. A small acquisition makes sense.
|
|
|
|
Post by tingtongtung on Dec 14, 2017 13:53:45 GMT -5
Thinking of acquisitions, perhaps they could be focused on a small acquisition of a company that can spread the footprint of Afrezza more rapidly. I'm not sure what form of company that would fit though. Just a thought. Vdex? I dont know what's the deal with acquisition that Mike seems to be saying.. May be they have a good plan, but its tough for us/outsiders to know as we dont have the full picture.. Ideally, they should go all-in in increasing the script numbers, and then go for getting acquired by someone. But, more ambitious people differ here - big risks => big reward. It's never simple with MNKD :-( |
|
|
|
Post by timri on Dec 14, 2017 13:58:16 GMT -5
Thinking of acquisitions, perhaps they could be focused on a small acquisition of a company that can spread the footprint of Afrezza more rapidly. I'm not sure what form of company that would fit though. Just a thought. Vdex? I dont know what's the deal with acquisition that Mike seems to be saying.. May be they have a good plan, but its tough for us/outsiders to know as we dont have the full picture.. Ideally, they should go all-in in increasing the script numbers, and then go for getting acquired by someone. But, more ambitious people differ here - big risks => big reward. It's never simple with MNKD :-( Idk if that would be a good idea. They might run into ramifications of prescribing their own drug. Idk if that’s allowed. |
|
